Abiopharma

Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting

Alam Kamran 🟢 acquired 590.0K shares (1 derivative) of Taysha Gene Therapies, Inc. (TSHA) at $4.86 ($1.1M) Transaction Date: Jan 12, 2026 | Filing ID: 000002

Nolan Sean P. 🟢 acquired 1.7M shares (1 derivative) of Taysha Gene Therapies, Inc. (TSHA) at $4.86 ($3.1M) Transaction Date: Jan 12, 2026 | Filing ID: 000002

Nagendran Sukumar 🟡 adjusted position in 501.0K shares (3 derivative) of Taysha Gene Therapies, Inc. (TSHA) at $4.86 ($2.7M) Transaction Date: Jan 12, 2026 | Filing ID: 000002

VESEY MICHAEL 🔴 sold 18.1K shares of Forian Inc. (FORA) at $2.12 Transaction Date: Jan 12, 2026 | Filing ID: 001191

New Form SCHEDULE 13G - Erasca, Inc. Filed: 2026-01-14 AccNo: 0001104659-26-003756 Size: 15 KB

(90% Positive) Oramed Pharmaceuticals Inc. (ORMP) Announces Business Combination

Johnson & Johnson - TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide

(99% Neutral) Kiniksa Pharmaceuticals (KNSA) Announces New Board Appointment

MAETZOLD DEREK J 🟢 acquired 124.4K shares (1 derivative) of CASTLE BIOSCIENCES INC (CSTL) Transaction Date: Jan 12, 2026 | Filing ID: 000002

TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide

New Form SCHEDULE 13G - Outset Medical, Inc. Filed: 2026-01-14 AccNo: 0001373604-26-000003 Size: 6 KB

Garg Pushkal 🟡 adjusted position in 2.3K shares of ALNYLAM PHARMACEUTICALS, INC. (ALNY) at $377.82 Transaction Date: Jan 11, 2026 | Filing ID: 000015

Director Greenstreet Yvonne 🟡 adjusted position in 9.4K shares of ALNYLAM PHARMACEUTICALS, INC. (ALNY) at $377.82 ($3.5M) Transaction Date: Jan 11, 2026 | Filing ID: 000014

Poulton Jeffrey V. 🟡 adjusted position in 3.4K shares of ALNYLAM PHARMACEUTICALS, INC. (ALNY) at $377.82 ($1.0M) Transaction Date: Jan 11, 2026 | Filing ID: 000013